Cyclophosphamide
Fallopian Tube Clear Cell Adenocarcinoma
Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05920798CT.gov Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | — | Recruiting | — | — | — |
NCT04919629CT.gov APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | — | Recruiting | — | — | — |
NCT02853318CT.gov Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Clear Cell Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Mayo Clinic | P2 | B · 63 |
| Carboplatin | NRG Oncology | P3 | BB |
| Olaparib | National Cancer Institute (NCI) | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | B |
| Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine | Mayo Clinic | P2 | B |
| Nogitecan | National Cancer Institute (NCI) | P2/3 | B |
| Pembrolizumab | Mayo Clinic | P2 | B |
+19 more in the Fallopian Tube Clear Cell Adenocarcinoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Cyclophosphamide in Fallopian Tube Clear Cell Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-fallopian-tube-clear-cell-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →